Loading stock data…
$1.97+0.01 (+0.63%)
TherapeuticsMD, Inc.
TherapeuticsMD, Inc. in the Healthcare sector is trading at $1.97 with a market capitalization of $25M. The stock is currently 33% below its 52-week high of $2.95, remaining 7.0% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $724,000↓ | $893,000↑ | $784,000↓ | $952,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | -$723,000↑ | -$1.50M↓ | -$830,000↓ | -$695,000 |
| Net Income | — | $95,000↑ | -$619,000↓ | $152,000↓ | $551,000 |
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to me...